The DOI matches its Crossref record.
Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX
Abstract
The current cure rate of 80% in childhood acute lymphoblastic leukemia (ALL) attests to the effectiveness of risk-directed therapy developed through well-designed clinical trials. The ongoing Total Therapy Study XV at St. Jude Children's Research Hospital was designed to further increase cure rate and to improve quality of life. The study consists of intensive systemic and intrathecal therapy but does not include cranial irradiation, irrespective of a patient's risk features. The intensity of postremission consolidation, continuation and reinduction therapy is based on the level of minimal residual disease at the end of induction, as measured by both flow cytometric detection of aberrant immunophenotypes and polymerase-chain-reaction amplification of clonal antigen-receptor gene rearrangements. Status of thiopurine methyltransferase is determined prospectively for treatment modification. Pharmacogenetic, pharmacodynamic, gene expression and proteomic profiling studies of host normal cells and leukemic cells are performed in parallel to elucidate the mechanisms of drug resistance and to advance our understanding of leukemogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Self-citationDeletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Den Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., Van Zutven, L. J., Beverloo, H. B., Van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 930
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Pui, C.-H., Sandlund, J. T., Pei, D., Campana, D., Rivera, G. K., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Howard, S. C., Hudson, M. M., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1616 · Cited by 463
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Soulier, J., Clappier, E., Cayuela, J.-M., Regnault, A., García-Peydró, M., Dombret, H., Baruchel, A., Toribio, M.-L., & Sigaux, F. (2005) · Blood · doi:10.1182/blood-2004-10-3900 · Cited by 383
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
Epigenetic regulation of gene expression in physiological and pathological brain processes
Gräff, J., Kim, D., Dobbin, M. M., & Tsai, L.-H. (2011) · Physiological Reviews · doi:10.1152/physrev.00012.2010 · Cited by 373
Prenatal exposure to drugs: effects on brain development and implications for policy and education
Thompson, B. L., Levitt, P., & Stanwood, G. D. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2598 · Cited by 367
Kuiper, R. P., Schoenmakers, E. F. P. M., van Reijmersdal, S. V., Hehir-Kwa, J. Y., van Kessel, A. G., van Leeuwen, F. N., & Hoogerbrugge, P. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404691 · Cited by 365
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc min mice
Myzak, M. C., Dashwood, W. M., Orner, G. A., Ho, E., & Dashwood, R. H. (2006) · The FASEB Journal · doi:10.1096/fj.05-4785fje · Cited by 344
Shen, S., Li, J., & Casaccia-Bonnefil, P. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200412101 · Cited by 319
Pui, C. H., Pei, D., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., Campana, D., Kun, L. E., Jeha, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.252 · Cited by 293
Breit, S., Stanulla, M., Flohr, T., Schrappe, M., Ludwig, W.-D., Tolle, G., Happich, M., Muckenthaler, M. U., & Kulozik, A. E. (2006) · Blood · doi:10.1182/blood-2005-12-4956 · Cited by 293
Clappier, E., Cuccuini, W., Kalota, A., Crinquette, A., Cayuela, J.-M., Dik, W. A., Langerak, A. W., Montpellier, B., Nadel, B., Walrafen, P., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064683 · Cited by 280
Graux, C., Cools, J., Michaux, L., Vandenberghe, P., & Hagemeijer, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404302 · Cited by 276
Personalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
Kuiper, R. P., Waanders, E., van der Velden, V. H. J., van Reijmersdal, S. V., Venkatachalam, R., Scheijen, B., Sonneveld, E., van Dongen, J. J. M., Veerman, A. J. P., van Leeuwen, F. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.87 · Cited by 268
Whitman, S. P., Ruppert, A. S., Radmacher, M. D., Mrózek, K., Paschka, P., Langer, C., Baldus, C. D., Wen, J., Racke, F., Powell, B. L., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107946 · Cited by 266
Kuang, S.-Q., Tong, W.-G., Yang, H., Lin, W., Lee, M. K., Fang, Z. H., Wei, Y., Jelinek, J., Issa, J.-P., & Garcia-Manero, G. (2008) · Leukemia · doi:10.1038/leu.2008.130 · Cited by 165
De Angulo, G., Yuen, C., Palla, S. L., Anderson, P. M., & Zweidler‐McKay, P. A. (2008) · Cancer · doi:10.1002/cncr.23168 · Cited by 123
Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression
Iga, J.-I., Ueno, S.-I., Yamauchi, K., Numata, S., Kinouchi, S., Tayoshi-Shibuya, S., Song, H., & Ohmori, T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.014 · Cited by 105
Toward an immune-mediated subtype of autism spectrum disorder
McDougle, C. J., Landino, S. M., Vahabzadeh, A., O’Rourke, J., Zurcher, N. R., Finger, B. C., Palumbo, M. L., Helt, J., Mullett, J. E., Hooker, J. M., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.048 · Cited by 95
The RUNX1–PU.1 axis in the control of hematopoiesis
Imperato, M. R., Cauchy, P., Obier, N., & Bonifer, C. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1762-8 · Cited by 94
Kuriyama, K., Honma, M., Soshi, T., Fujii, T., & Kim, Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2353-x · Cited by 54
GSK-3 inhibition sensitizes acute myeloid leukemia cells to 1,25D-mediated differentiation
Gupta, K., Stefan, T., Ignatz-Hoover, J., Moreton, S., Parizher, G., Saunthararajah, Y., & Wald, D. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2290 · Cited by 44
Kuriyama, K., Honma, M., Yoshiike, T., & Kim, Y. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.045 · Cited by 36
Gagné, V., Rousseau, J., Labuda, M., Sharif-Askari, B., Brukner, I., Laverdière, C., Ceppi, F., Sallan, S. E., Silverman, L. B., Neuberg, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1215 · Cited by 28
Metadata
- Venue
- Annals of Hematology
- Published
- 2004-01-24
- Volume
- 83
- Issue
- S1
- Pages
- S59-S137
- ISSN
- 0939-5555
- 1432-0584
- OpenAlex
- W70913691
- Cited by
- 365
- References
- 0
- FWCI
- 28.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.